Anixa Biosciences, Inc. (NASDAQ:ANIX) Director Arnold M. Baskies Buys 5,000 Shares of Stock

Anixa Biosciences, Inc. (NASDAQ:ANIX) Director Arnold M. Baskies acquired 5,000 shares of Anixa Biosciences stock in a transaction that occurred on Tuesday, January 28th. The shares were bought at an average price of $2.82 per share, with a total value of $14,100.00. Following the transaction, the director now directly owns 120,000 shares in the company, valued at approximately $338,400. This trade represents a 4.35 % increase in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link.

Anixa Biosciences Price Performance

ANIX opened at $3.00 on Thursday. The stock’s 50 day moving average price is $2.75 and its 200 day moving average price is $3.05. The stock has a market cap of $96.60 million, a P/E ratio of -7.69 and a beta of 0.90. Anixa Biosciences, Inc. has a 12 month low of $2.07 and a 12 month high of $4.70.

Anixa Biosciences (NASDAQ:ANIX) last issued its quarterly earnings results on Friday, January 10th. The company reported ($0.09) EPS for the quarter, beating analysts’ consensus estimates of ($0.11) by $0.02. Equities analysts anticipate that Anixa Biosciences, Inc. will post -0.46 EPS for the current year.

Hedge Funds Weigh In On Anixa Biosciences

Several large investors have recently bought and sold shares of ANIX. International Assets Investment Management LLC lifted its stake in shares of Anixa Biosciences by 170.0% in the 3rd quarter. International Assets Investment Management LLC now owns 37,800 shares of the company’s stock worth $1,190,000 after acquiring an additional 23,800 shares during the period. Tyler Stone Wealth Management raised its holdings in Anixa Biosciences by 100.0% during the third quarter. Tyler Stone Wealth Management now owns 42,016 shares of the company’s stock worth $132,000 after purchasing an additional 21,008 shares in the last quarter. Virtu Financial LLC acquired a new stake in Anixa Biosciences in the third quarter worth approximately $34,000. Finally, Westside Investment Management Inc. boosted its stake in Anixa Biosciences by 151.8% during the 3rd quarter. Westside Investment Management Inc. now owns 35,000 shares of the company’s stock valued at $110,000 after purchasing an additional 21,100 shares in the last quarter. Institutional investors and hedge funds own 29.13% of the company’s stock.

Analysts Set New Price Targets

A number of equities research analysts have issued reports on the company. HC Wainwright reiterated a “buy” rating and issued a $7.00 target price on shares of Anixa Biosciences in a research note on Tuesday, November 19th. D. Boral Capital reiterated a “buy” rating and issued a $10.00 price objective on shares of Anixa Biosciences in a research report on Wednesday, January 22nd.

About Anixa Biosciences

Anixa Biosciences, Inc, a biotechnology company, develops therapies and vaccines focusing on critical unmet needs in oncology and infectious diseases. The company's therapeutics programs include the development of a chimeric endocrine receptor T-cell therapy, a novel form of chimeric antigen receptor T-cell (CAR-T) technology focusing on the treatment of ovarian cancer.